ɬ﷬

Journal News

New clues reveal how cells respond to stress

Emily Ulrich
May 15, 2025

Inflammasome protein complexes form in response to signals associated with danger, such as an infection or environmental stress, and trigger the innate immune response. The serine protease dipeptidyl peptidase 9, or DPP9, forms a dimer in its active conformation and interacts with components of inflammasomes to prevent unnecessary activation. Scientists know that synthetic inhibitors of DPP9 activate certain inflammasomes. However, whether a cell-intrinsic molecule can inhibit this enzyme remains an open question. Therefore, Lydia Tsamouri, Jeffrey Hsiao and colleagues from the Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center investigated DPP9 interaction partners. They examined a connection between DPP9 and redox sensor KEAP1 in their recent Journal of Biological Chemistry .

Cryogenic electron microscopy structure of the active NLRP3 inflammasome.
Cryogenic electron microscopy structure of the active NLRP3 inflammasome.

Using a fluorogenic probe that functions as a DPP9 substrate, the authors established that KEAP1 inhibits DPP9 activity in cells. They also found that KEAP1 can only inhibit DPP9 when both are introduced into cells at the same time via transfection with complementary DNA, or cDNA, that encodes each protein, before DPP9 dimerizes; newly introduced KEAP1 could not inhibit DPP9 already present in cells. The researchers hypothesized that KEAP1 interacts with DPP9 in a state different from its folded dimeric structure and that a cellular event or biomolecule could force DPP9 to adopt this alternative conformation. They tested multiple compounds, including electron transport chain inhibitors and oxidants like hydrogen peroxide, but they have not yet found a condition that leads to KEAP1–DPP9 complex formation and DPP9 inactivation.

Future experiments will focus on identifying a signal or molecules that could change DPP9’s conformation and whether the DPP9–KEAP1 interaction directly initiates inflammasome activation. Outlining the full DPP9 pathway involving inflammasomes will help scientists understand how cells convert danger signals into immune action and restrain unnecessary activation.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Emily Ulrich

Emily Ulrich is the ASBMB’s science editor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.

Unraveling cancer’s spaghetti proteins
Profile

Unraveling cancer’s spaghetti proteins

Aug. 13, 2025

MOSAIC scholar Katie Dunleavy investigates how Aurora kinase A shields oncogene c-MYC from degradation, using cutting-edge techniques to uncover new strategies targeting “undruggable” molecules.

How HCMV hijacks host cells — and beyond
Profile

How HCMV hijacks host cells — and beyond

Aug. 12, 2025

Ileana Cristea, an ASBMB Breakthroughs webinar speaker, presented her research on how viruses reprogram cell structure and metabolism to enhance infection and how these mechanisms might link viral infections to cancer and other diseases.

Understanding the lipid link to gene expression in the nucleus
Profile

Understanding the lipid link to gene expression in the nucleus

Aug. 11, 2025

Ray Blind, an ASBMB Breakthroughs speaker, presented his research on how lipids and sugars in the cell nucleus are involved in signaling and gene expression and how these pathways could be targeted to identify therapeutics for diseases like cancer.

Receptor antagonist reduces age-related bone loss in mice
Journal News

Receptor antagonist reduces age-related bone loss in mice

Aug. 6, 2025

Receptor antagonist reduces bone loss and promotes osteoblast activity in aging mice, highlighting its potential to treat osteoporosis. Read more about this recent JBC paper.

Engineered fusion protein targets kiwifruit pathogen
Journal News

Engineered fusion protein targets kiwifruit pathogen

Aug. 6, 2025

Synthetic protein selectively kills kiwifruit pathogen, offering a promising biocontrol strategy for agriculture. Read more about this recent JBC paper.